期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

管腔型乳腺癌的分型及其与临床病理特征的关系 被引量：3

原文传递
导出
摘要 管腔型乳腺癌作为乳腺癌分子分型中发病率最高的一种类型，因其拥有针对性的治疗成为乳腺癌临床和病理研究的热点。本研究按照第12届 St Gallen 乳腺癌国际共识进行分型诊断，筛选出142例管腔型乳腺癌患者入组，探讨管腔型乳腺癌的分型，分析管腔型乳腺癌的分子分型与临床病理特征的关系。
作者 王学丽 郝青 陈青
机构地区 山东省滨州市中心医院病理科
出处 《国际肿瘤学杂志》 CAS 2015年第7期557-558,共2页 Journal of International Oncology
关键词 临床病理特征 乳腺癌患者 分子分型 管腔 分型诊断 发病率
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer ; highlights of the St. GallenInternational Expert Consensus on the Primary Therapy of Early BreastCancer 2011 [J]. Ann Oncol, 2011, 22(8) : 17364747.
  • 2Hammond ME,Hayes DF, Dowsett M,et al. American Society ofClinical Oncology/College of American Pathologists guideline recom-mendations for immunohistochemicai testing of estrogen and progester-one receptors in breast cancer [ J ]. J Clin Oncol, 2010,28(16):2784-2795.
  • 3Guideline Recommendations for HER2 Detection in Breast CancerGroup. Guidelines for HER2 detection in breast cancer, the 2009 ver-sion [J]. Zhonghua Bing Li Xue Za Zhi, 2009 , 38(12) : 836-840.
  • 4Donsett M, Nielsen TO, A Hem R, et al. Assessment of Ki67 inbreast cancer : recommendations from the International Ki67 in BreastCancer working group[ J]. Natl Cancer Inst, 2011,103(22) : 1656-1664.
  • 5Sorlie T,Peron CM, Tibshirani R, et al. Gene expression patterns ofbreast carcinomas distinguish tumor subclasses with clinical implica-tions [J]. Proc Natl Acad Sci USA, 2001,98(19) : 10869-10874.
  • 6Peron CM, Sorlie T, Eisen MB, et al. Molecular portraits of humanbreast tumours[ J]. Nature, 2000,406(6797) : 747-752.
  • 7Zhao J, Liu H, Wang M, et al. Characteristics and prognosis formolecular breast cancer subtypes in Chinese women[ J]. J Surg On-col, 2009, 100(2) : 89-94.
  • 8胡慧,刘倩,徐玲,叶京明,赵建新,段学宁,刘荫华.乳腺癌临床病理分类与临床病理特征研究[J].中华外科杂志,2014,52(2):113-116. 被引量：22
  • 9Paik S, Shak S, Tang G, et al. A multigene assay to predict recur-rence of tamoxifen-treated, node-negative breast cancer[ J]. N Engl JMed, 2004,351(27) : 2817-2826.
  • 10Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of70-gene signature to predict prognosis of patients with node-negativebreast cancer:a prospective community-based feasibility study ( RAS-TER)[J]. Lancet Oncol, 2007, 8(12) : 1079-1087.

二级参考文献12

  • 1Goldhirsch A,Wood WC,Coates AS. Strategies for subtypes--dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].{H}ANNALS OF ONCOLOGY,2011,(8):1736-1747.
  • 2Hammond ME,Hayes DF,Dowsett M. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)[J].{H}ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE,2010,(7):e48-e72.
  • 3Wolff AC,Hammond ME,Schwartz JN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].{H}ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE,2007,(1):18-43.
  • 4Cheang MC,Chia SK,Voduc D. Ki67 index,HER2status,and prognosis of patients with luminal b breast cancer[J].{H}JOURNAL OF THE NATIONAL CANCER INSTITUTE,2009,(10):736-750.
  • 5Kay E,O'Grady A,Morgan JM. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing[J].{H}Journal of Clinical Pathology,2004,(11):1140-1144.
  • 6Edge SB,Compton CC. The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future ofTNM[J].{H}ANNALS OF SURGICAL ONCOLOGY,2010,(6):1471-1474.
  • 7Tavassoli FA,Devilee P,World Health Organization. Pathology and genetics of tumours of the breast and female genital organs[M].New York:WHO Publications Center,2003.
  • 8Perou CM,S(o)rlie T,Eisen MB. Molecular portraits of human breast tumours[J].{H}NATURE,2000,(6797):747-752.
  • 9Jones RL,Salter J,AHern R. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer[J].{H}Breast Cancer Research and Treatment,2009,(1):53-68.
  • 10Viale G,Giobbie-Hurder A,Regan MM. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer:results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole[J].{H}Journal of Clinical Oncology,2008,(34):5569-5575.

共引文献21

同被引文献39

  • 1李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症,2004,23(10):1176-1179. 被引量：126
  • 2杨名添,戎铁华,黄植蕃,曾灿光,龙浩,傅剑华,林鹏,王欣,王思愚,王曦,唐军.可手术乳腺癌6263例临床分析[J].癌症,2005,24(3):327-331. 被引量：46
  • 3Goldhirsch A,Wood WC,Coates AS,et al. Strategies forsubtypes-dealing with the diversity of breast cancer : highlights ofthe St. Gallen International Expert Consensus on the PrimaryTherapy of Early Breast Cancer 2011 [ J]. Ann Oncol,2011 ,22(8):1736-1747. DOI: 10. 1093/annonc/mdr304.
  • 4Elston CW, Ellis 10. Pathological prognostic factors in breastcancer. I. The value of histological grade in breast cancer:experience from a large study with long-term follow-up [ J ],Histopathology, 1991,19 (5 ) :403410. DOI: 10. 1111/j. 1365-2559.1991. tb00229.x.
  • 5Goldhirsch A, Wood WC, Gelber RD, et al. Progress andpromise : highlights of the international expert consensus on theprimary therapy of early breast cancer 2007 [ J ]. Ann Oncol,2007,18(7) :1133-1144. D01:10. 1093/annonc/mdm271.
  • 6Seshie B, Adu-Aryee NA, Dedey F, et al. A retrospectiveanalysis of breast cancer subtype based on ER/PR and HER2status in Ghanaian patients at the Korle Bu Teaching Hospital,Ghana[ J]. BMC Clin Pathol, 2015, 15: 14. DOI: 10. 1186/sl2907-015-00144.
  • 7Zhu X, Ying J,Wang F, et al. Estrogen receptor, progesteronereceptor, and human epidermal growth factor receptor 2 status ininvasive breast cancer : a 3 ,198 cases study at National CancerCenter, China[ J] . Breast Cancer Res Treat,2014,147 (3 ) :551-555. DOI: 10.1007/sl0549-014-3136-y.
  • 8Kurian AW, Fish K, Shema SJ, et al. Lifetime risks of specificbreast cancer subtypes among women in four racial/ethnic groups[J]. Breast Cancer Res, 2010, 12 ( 6 ) : R99. DOI; 10. 1186/bcr2780.
  • 9Van Calster B, Vanden BI, Drijkoningen M, et al. Axillarylymph node status of operable breast cancers by combined steroidreceptor and HER-2 status : triple positive tumours are more likelylymph node positive[ J]. Breast Cancer Res Treat?2009 ,113( 1):181-187. DOI: 10.1007A10549-008-9914-7.
  • 10He Z Y, Wu S G, Yang Q, et al. Breast cancer subtype isassociated with axillary lymph node metastasis : A retrospectivecohort study [ J ]. Medicine ( Baltimore),2015 ,94 (48 ) ; e2213.DOI: 10. 1097/MD. 0000000000002213.

引证文献3

二级引证文献70

国际肿瘤学杂志
2015年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部